English
Regional settings| Spread | 0.07 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 15.37 |
| Open | 15.34 |
| 1-Year Change | 58.31% |
| Day's Range | 15.25 - 15.37 |
Icosavax Inc. is a biopharmaceutical company. The Company uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on respiratory diseases. Its VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens. The Company's pipeline includes vaccine candidates targeting viral causes of pneumonia. Its vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). The Company is also developing two severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates, IVX-411 and IVX-421, with a Phase I/II clinical trial of IVX-411.
BRIEF: For the nine months ended 30 September 2021, Icosavax Inc revenues totaled $5.7M. Net loss totaled to $48.8M.
